Events

2018 News Releases



Webcast ImageWebcast
Rigel Pharmaceuticals FDA Approval of TAVALISSE (Replay)
April 17, 2018 at 5:00 p.m. ET
Webcast ImageWebcast
Q1 2018 Rigel Pharmaceuticals Earnings Call (Live)
May 1, 2018 at 2:00 p.m. PT
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle  
04/24/18Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., April 24, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2018 financial results after market close on Tuesday, May 1, 2018.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and provide a company update. Participants can access the live conference call by dialing 855-892-1489... 
 Printer Friendly Version
04/19/18Rigel Announces Pricing Of Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., April 19, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of its previously announced underwritten public offering of 16,000,000 shares of its common stock, offered at a price of $3.90 per share to the public.  The gross proceeds to Rigel from this offering are expected to be $62.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Rigel.  All of the shares in t... 
 Printer Friendly Version
04/18/18Rigel Announces Proposed Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., April 18, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it intends to offer and sell up to 15,000,000 shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock sold in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assuranc... 
 Printer Friendly Version
04/17/18Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients
TAVALISSE Offers First-in-Class Treatment with Unique Mechanism of Action U.S. Commercial Launch Expected in Late May 2018 Conference Call and Webcast to be Held Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif., April 17, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the U.S. Food and Drug Administration (FDA) approved TAVALISSE™ (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immun... 
 Printer Friendly Version
04/12/18Rigel Makes Statement Regarding Website Error
SOUTH SAN FRANCISCO, Calif., April 12, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), reported that due to an error by the external host of its investor relations website, inaccurate information was displayed regarding the U.S. Food and Drug Administration's (FDA) review of the New Drug Application (NDA) for fostamatinib for the treatment of adult patients with chronic immune thrombocytopenia (ITP).  The website has been corrected.  The FDA is continuing its review of the NDA a... 
 Printer Friendly Version
04/03/18Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy
Company to host a conference call today at 8:00AM EDT to Discuss the Study Results SOUTH SAN FRANCISCO, Calif., April 3, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today announced topline data from its proof-of-concept Phase 2 study of fostamatinib in patients with IgA nephropathy (IgAN), an orphan autoimmune disease of the kidneys. The trial did not achieve statistical significance for its primary endpoint, which was mean change in proteinuria comparing fostamatinib do... 
 Printer Friendly Version
03/06/18Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update
Conference Call and Webcast Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif., March 6, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year end 2017. Recent Achievements The U.S. Food and Drug Administration (FDA) is continuing its review of Rigel's New Drug Application (NDA) for fostamatinib for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Prescription Drug User F... 
 Printer Friendly Version
03/01/18Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America
SOUTH SAN FRANCISCO, Calif., March 1, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib data from its FIT Phase 3 extension study (FIT3) in patients with chronic immune thrombocytopenia (ITP) and preliminary data from its SOAR Phase 2 clinical study in patients with warm antibody autoimmune hemolytic anemia (AIHA) will be presented at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America on March 8 – 10, 2018 in San... 
 Printer Friendly Version
02/27/18Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2017 financial results after market close on Tuesday, March 6, 2018.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and provide a company update. Participants can access the live conference call by diali... 
 Printer Friendly Version
01/04/18Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 4, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present an update on its product pipeline and a financial overview at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 10, 2018, at 1:30pm PST (see webcast details below). Rigel's presentation will include a review of the company's New Drug Application... 
 Printer Friendly Version